Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models
Hoa T.T. Ha, … , Margit Burmeister, Long N. Nguyen
Hoa T.T. Ha, … , Margit Burmeister, Long N. Nguyen
Published March 7, 2024
Citation Information: JCI Insight. 2024;9(8):e175462. https://doi.org/10.1172/jci.insight.175462.
View: Text | PDF
Research Article Aging Metabolism

Lack of SPNS1 results in accumulation of lysolipids and lysosomal storage disease in mouse models

  • Text
  • PDF
Abstract

Accumulation of sphingolipids, especially sphingosines, in the lysosomes is a key driver of several lysosomal storage diseases. The transport mechanism for sphingolipids from the lysosome remains unclear. Here, we identified SPNS1, which shares the highest homology to SPNS2, a sphingosine-1-phosphate (S1P) transporter, functions as a transporter for lysolipids from the lysosome. We generated Spns1-KO cells and mice and employed lipidomic and metabolomic approaches to reveal SPNS1 ligand identity. Global KO of Spns1 caused embryonic lethality between E12.5 and E13.5 and an accumulation of sphingosine, lysophosphatidylcholines (LPC), and lysophosphatidylethanolamines (LPE) in the fetal livers. Similarly, metabolomic analysis of livers from postnatal Spns1-KO mice presented an accumulation of sphingosines and lysoglycerophospholipids including LPC and LPE. Subsequently, biochemical assays showed that SPNS1 is required for LPC and sphingosine release from lysosomes. The accumulation of these lysolipids in the lysosomes of Spns1-KO mice affected liver functions and altered the PI3K/AKT signaling pathway. Furthermore, we identified 3 human siblings with a homozygous variant in the SPNS1 gene. These patients suffer from developmental delay, neurological impairment, intellectual disability, and cerebellar hypoplasia. These results reveal a critical role of SPNS1 as a promiscuous lysolipid transporter in the lysosomes and link its physiological functions with lysosomal storage diseases.

Authors

Hoa T.T. Ha, SiYi Liu, Xuan T.A. Nguyen, Linh K. Vo, Nancy C.P. Leong, Dat T. Nguyen, Shivaranjani Balamurugan, Pei Yen Lim, YaJun Wu, Eunju Seong, Toan Q. Nguyen, Jeongah Oh, Markus R. Wenk, Amaury Cazenave-Gassiot, Zuhal Yapici, Wei-Yi Ong, Margit Burmeister, Long N. Nguyen

×

Figure 4

Spns1-KO mice exhibit lysosomal storage phenotypes.

Options: View larger image (or click on image) Download as PowerPoint
Spns1-KO mice exhibit lysosomal storage phenotypes.
(A) Illustration of ...
(A) Illustration of the postnatal deletion strategy of Spns1 using Rosa26Cre-ERT2 mice. (B) Reduction of body weights of gSpns1-cKO male and female mice 2 weeks after tamoxifen treatment. Each symbol represents 1 mouse. (C) Representative images of a control and a gSpns1-cKO mouse. (D) Increased number of white blood cells (WBC) in gSpns1-cKO mice compared with controls. Each symbol represents 1 mouse. (E) Representative images of livers from a control and a gSpns1-cKO mouse. (F) Increased liver weights in gSpns1-cKO mice compared with the controls of the same age. Each symbol represents 1 mouse. (G) Representative images of H&E staining of liver sections from control and gSpns1-cKO mice. Livers of gSpns1-cKO mice were presented a foamy phenotype. n = 3 per genotype. Scale bar: 50 μm. (H) Representative of immunostaining images of liver sections from control and gSpns1-cKO mice with cathepsin B and LAMP1 or with Mac-2 for macrophages. Scale bar: 20 μm. n = 3 per genotype. (I) Quantification of cathepsin B fluorescence intensity from H. (J) Numeration of Mac-2+ cells from H. Each symbol represents one section from n = 3 mice per genotype. (K and L) Western blot analysis of cathepsin B and LC3B proteins from whole liver protein lysates of control and gSpns1-cKO mice. Cathepsin B processing was defective in the livers of gSpns1-cKO mice (arrow). n = 4 per genotype. (M) Quantification of total LC3B-II bands from L. (N and O) The levels of lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), ceramides, and sphingosines from whole livers and lysosomal fractions (F1 and F2) of control and gSpns1-cKO mice, respectively. n = 4–5 for whole liver. n = 3 per genotype for lysosomes. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are expressed as mean ± SD. Statistical significance was determined by 2-tailed unpaired t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts